Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
| Condition | Atopic Dermatitis, Eczema |
|---|---|
| Phase | Phase 3 |
| Sponsor | Almirall, S.A. |
| Status | Completed |
| Enrollment | 260 participants |
| Interventions | Lebrikizumab |
| Start date | Nov 20, 2023 |
| Completion date | Jun 25, 2025 |
| Results posted | Jul 17, 2026 |
Summary
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24
| Lebrikizumab | 74.7 Percentage of participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen